These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38782175)

  • 1. Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis.
    De Vincentis A; Ampuero J; Terracciani F; D'Amato D; Gerussi A; Cristoferi L; Cazzagon N; Bonaiuto E; Floreani A; Calvaruso V; Cadamuro L; Degasperi E; Morgando A; Vanni E; Lleo A; Colapietro F; Alvaro D; Castellaneta A; Labanca S; Viganò M; Distefano M; Pace Palitti V; Ricci C; De Matthaeis N; Marzioni M; Gómez-Dominguez E; Montero JL; Molina E; Garcia-Buey L; Casado M; Berenguer M; Conde I; Simon MA; Fuentes J; Costa-Moreira P; Macedo G; Jorquera F; Morillas RM; Presa J; Sousa JM; Gomes D; Santos L; Olveira A; Hernandez-Guerra M; Aburruza L; Santos A; Carvalho A; Uriz J; Gutierrez ML; Perez E; Chessa L; Pellicelli A; Marignani M; Muratori L; Niro GA; Brunetto M; Ponziani FR; Pompili M; Marra F; Galli A; Mussetto A; Alagna G; Simone L; Bertino G; Rosina F; Cozzolongo R; Russello M; Baiocchi L; Saitta C; Terreni N; Zolfino T; Rigamonti C; Vigano R; Cuccorese G; Pozzoni P; Pedone C; Grasso S; Picardi A; Invernizzi P; Sacco R; Izzi A; Fernandez-Rodriguez C; Vespasiani-Gentilucci U; Carbone M;
    Clin Gastroenterol Hepatol; 2024 Oct; 22(10):2062-2074.e11. PubMed ID: 38782175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world experience with obeticholic acid in patients with primary biliary cholangitis.
    D'Amato D; De Vincentis A; Malinverno F; Viganò M; Alvaro D; Pompili M; Picciotto A; Palitti VP; Russello M; Storato S; Pigozzi MG; Calvaruso V; De Gasperi E; Lleo A; Castellaneta A; Pellicelli A; Cazzagon N; Floreani A; Muratori L; Fagiuoli S; Niro GA; Feletti V; Cozzolongo R; Terreni N; Marzioni M; Pellicano R; Pozzoni P; Baiocchi L; Chessa L; Rosina F; Bertino G; Vinci M; Morgando A; Vanni E; Scifo G; Sacco R; D'Antò M; Bellia V; Boldizzoni R; Casella S; Omazzi B; Poggi G; Cristoferi L; Gerussi A; Ronca V; Venere R; Ponziani F; Cannavò M; Mussetto A; Fontana R; Losito F; Frazzetto E; Distefano M; Colapietro F; Labanca S; Marconi G; Grassi G; Galati G; O'Donnell SE; Mancuso C; Mulinacci G; Palermo A; Claar E; Izzi A; Picardi A; Invernizzi P; Carbone M; Vespasiani-Gentilucci U;
    JHEP Rep; 2021 Apr; 3(2):100248. PubMed ID: 33681748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice.
    Gómez E; Montero JL; Molina E; García-Buey L; Casado M; Fuentes J; Simón MA; Díaz-González A; Jorquera F; Morillas RM; Presa J; Berenguer M; Conde MI; Olveira A; Macedo G; Garrido I; Hernández-Guerra M; Olivas I; Rodríguez-Tajes S; Londoño M; Sousa JM; Ampuero J; Romero-González E; González-Padilla S; Escudero-García D; Carvalho A; Santos A; Gutiérrez ML; Pérez-Fernández E; Aburruza L; Uriz J; Gomes D; Santos L; Martínez-González J; Albillos A; Fernández-Rodríguez CM
    Aliment Pharmacol Ther; 2024 Jun; 59(12):1604-1615. PubMed ID: 38690746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
    Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL;
    J Hepatol; 2020 Jul; 73(1):94-101. PubMed ID: 32165251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis.
    Soret PA; Lam L; Carrat F; Smets L; Berg T; Carbone M; Invernizzi P; Leroy V; Trivedi P; Cazzagon N; Weiler-Normann C; Alric L; Rosa-Hezode I; Heurgué A; Cervoni JP; Dumortier J; Potier P; Roux O; Silvain C; Bureau C; Anty R; Larrey D; Levy C; Pares A; Schramm C; Nevens F; Chazouillères O; Corpechot C
    Aliment Pharmacol Ther; 2021 May; 53(10):1138-1146. PubMed ID: 33764590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
    Hirschfield GM; Mason A; Luketic V; Lindor K; Gordon SC; Mayo M; Kowdley KV; Vincent C; Bodhenheimer HC; Parés A; Trauner M; Marschall HU; Adorini L; Sciacca C; Beecher-Jones T; Castelloe E; Böhm O; Shapiro D
    Gastroenterology; 2015 Apr; 148(4):751-61.e8. PubMed ID: 25500425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival.
    Murillo Perez CF; Ioannou S; Hassanally I; Trivedi PJ; Corpechot C; van der Meer AJ; Lammers WJ; Battezzati PM; Lindor KD; Nevens F; Kowdley KV; Bruns T; Cazzagon N; Floreani A; Mason AL; Gulamhusein A; Ponsioen CY; Carbone M; Lleo A; Mayo MJ; Dalekos GN; Gatselis NK; Thorburn D; Verhelst X; Parés A; Londoño MC; Janssen HLA; Invernizzi P; Vuppalanchi R; Hirschfield GM; Hansen BE; Levy C;
    Liver Int; 2023 Jul; 43(7):1497-1506. PubMed ID: 37157905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for decompensating events in patients with cirrhosis with primary biliary cholangitis under different lines of therapy.
    Ampuero J; Lucena A; Berenguer M; Hernández-Guerra M; Molina E; Gómez-Camarero J; Valdivia C; Gómez E; Casado M; Álvarez-Navascuez C; Jorquera F; García-Buey L; Díaz-González Á; Morillas R; García-Retortillo M; Sousa JM; Pérez-Medrano I; Simón MÁ; Martínez J; Arenas J; Londoño MC; Olveira A; Fernández-Rodríguez C;
    Hepatology; 2024 Oct; 80(4):791-806. PubMed ID: 38447019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.
    Hirschfield GM; Dyson JK; Alexander GJM; Chapman MH; Collier J; Hübscher S; Patanwala I; Pereira SP; Thain C; Thorburn D; Tiniakos D; Walmsley M; Webster G; Jones DEJ
    Gut; 2018 Sep; 67(9):1568-1594. PubMed ID: 29593060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
    Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
    Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid.
    Gomez E; Garcia Buey L; Molina E; Casado M; Conde I; Berenguer M; Jorquera F; Simón MA; Olveira A; Hernández-Guerra M; Mesquita M; Presa J; Costa-Moreira P; Macedo G; Arenas JI; Manuel Sousa J; Ampuero J; Morillas RM; Santos A; De Carvalho A; Uriz J; Carrión JA; Luisa Gutiérrez M; Pérez-Fernández E; Fernández-Rodríguez CM;
    Aliment Pharmacol Ther; 2021 Feb; 53(4):519-530. PubMed ID: 33314220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study.
    Reig A; Álvarez-Navascués C; Vergara M; Gómez-Domínguez E; Gallego-Moya A; Pérez-Medrano IM; Fábrega E; Hernández-Guerra M; Berenguer M; Estevez P; Arencibia A; Morillas RM; Horta D; Albillos A; Casado M; De la Cruz G; Fernandez-Bonilla E; Molina E; Hijona L; Diago M; Fernández-Rodriguez CM; González-Santiago JM; Sala M; Gómez-Camarero J; Romero-Gomez M; Suárez F; Vargas V; Ferre-Aracil C; Andrade RJ; Chahri N; Parés A
    Am J Gastroenterol; 2021 Nov; 116(11):2250-2257. PubMed ID: 34158466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of primary biliary cholangitis prior to obeticholic acid availability.
    Durazzo M; Bonetto S; Fagoonee S; Morgando A; Pellicano R
    Minerva Med; 2018 Dec; 109(6):410-417. PubMed ID: 30022645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls.
    Murillo Perez CF; Fisher H; Hiu S; Kareithi D; Adekunle F; Mayne T; Malecha E; Ness E; van der Meer AJ; Lammers WJ; Trivedi PJ; Battezzati PM; Nevens F; Kowdley KV; Bruns T; Cazzagon N; Floreani A; Mason AL; Parés A; Londoño MC; Invernizzi P; Carbone M; Lleo A; Mayo MJ; Dalekos GN; Gatselis NK; Thorburn D; Verhelst X; Gulamhusein A; Janssen HLA; Smith R; Flack S; Mulcahy V; Trauner M; Bowlus CL; Lindor KD; Corpechot C; Jones D; Mells G; Hirschfield GM; Wason J; Hansen BE;
    Gastroenterology; 2022 Dec; 163(6):1630-1642.e3. PubMed ID: 36150526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase.
    Murillo Perez CF; Harms MH; Lindor KD; van Buuren HR; Hirschfield GM; Corpechot C; van der Meer AJ; Feld JJ; Gulamhusein A; Lammers WJ; Ponsioen CY; Carbone M; Mason AL; Mayo MJ; Invernizzi P; Battezzati PM; Floreani A; Lleo A; Nevens F; Kowdley KV; Bruns T; Dalekos GN; Gatselis NK; Thorburn D; Trivedi PJ; Verhelst X; Parés A; Janssen HLA; Hansen BE;
    Am J Gastroenterol; 2020 Jul; 115(7):1066-1074. PubMed ID: 32618657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid.
    De Vincentis A; D'Amato D; Cristoferi L; Gerussi A; Malinverno F; Lleo A; Colapietro F; Marra F; Galli A; Fiorini C; Coco B; Brunetto M; Niro GA; Cotugno R; Saitta C; Cozzolongo R; Losito F; Giannini EG; Labanca S; Marzioni M; Marconi G; Morgando A; Pellicano R; Vanni E; Cazzagon N; Floreani A; Chessa L; Morelli O; Muratori L; Pellicelli A; Pompili M; Ponziani F; Tortora A; Rosina F; Russello M; Cannavò M; Simone L; Storato S; Viganò M; Abenavoli L; D'Antò M; De Gasperi E; Distefano M; Scifo G; Zolfino T; Calvaruso V; Cuccorese G; Palitti VP; Sacco R; Bertino G; Frazzetto E; Alvaro D; Mulinacci G; Palermo A; Scaravaglio M; Terracciani F; Galati G; Ronca V; Zuin M; Claar E; Izzi A; Picardi A; Invernizzi P; Vespasiani-Gentilucci U; Carbone M;
    Liver Int; 2022 Nov; 42(11):2453-2465. PubMed ID: 35932095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excellent outcome in patients with primary biliary cholangitis in Northwest Italy followed up for up to 30 years.
    Rigamonti C; De Benedittis C; Labanca S; Vanni E; Morgando A; Manfredi GF; Azzolina D; Cittone MG; Giannini EG; Saracco GM; Pirisi M
    Eur J Gastroenterol Hepatol; 2023 Aug; 35(8):899-906. PubMed ID: 37395243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis.
    Harms MH; Hirschfield GM; Floreani A; Mayo MJ; Parés A; Liberman A; Malecha ES; Pencek R; MacConell L; Hansen BE
    JHEP Rep; 2021 Feb; 3(1):100191. PubMed ID: 33319187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.